MedTrace Logo

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

NCT04478708 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-12-10

Study results available
· View outcomes & findings →

Summary

The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity

Conditions

Interventions

BIOLOGICAL

maridebart cafraglutide

Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.

DRUG

Placebo

Participants will receive placebo as a single dose in Part A and multiple doses in Part B.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-07
Primary Completion
2022-11-18
Completion
2022-11-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04478708 on ClinicalTrials.gov